Patent US3668075A successfully refreshed from Google Patents.
US3668075A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Growth inhibitions of selective mycoplasmas
Assignee: F Hoffmann La Roche AG
•
Filing: 1968-10-04
•
Granted: 1972-06-06
•
Expires: 1988-10-04
Abstract
Abstract The use of certain heparinoid compounds to selectively inhibit the growth of mycoplasmas is described. The invention provides a practical means for facilitating the selective identification of mycoplasmas. The identification of mycoplasmas isolated from man is especially useful as a diagnostic aid in prescribing treatment for diseases caused by these microorganisms. Additionally, the invention provides a means of preventing the growth of mycoplasmas in culture media especially media used for tissue cultures in which mycoplasmas frequently occur as undesirable contaminants.
Inventors
- 👤 Thomas Cekoric Jr
- 👤 George Evans
- 👤 Ronald Searcy
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 10:00
CPC Classifications
C; C12; C12N; C12N1/00; C12N1/38; Y; Y10; Y10S; Y10S435/00; Y10S435/80; Y10S435/805; Y10S435/8215; Y10S435/822; Y10S435/87
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
55 words
A composition for selectively inhibiting the growth of mycoplasmas in culture media comprising a disc impregnated with a cOmpound selected from the group consisting of a salt of polyanethol sulfonic acid and a salt of sulfated polymannuronic acid, there being present on such disc from about 0.1 mg. to about 1.0 mg of the compound.
Claim 2
Dependent Claim
99 words
A process for selectively inhibiting the growth of mycoplasmas selected from the group consisting of M. hominis, type 1; M. hominis, type 2 (M. arthritidis); M. fermentans; M. pulmonis; M. pneumoniae; M. orale, type 2; M. orale, type 1; and mixtures thereof, which comprises contacting a broth or agar medium containing the mycoplasma with a salt of polyanethol sulfonic acid, there being used in said process, based on the weight of the medium, from about 0.5 percent to about 1.0 percent of the polyanethol sulfonic acid salt, incubating at about 37* C. and observing the growth of the culture.
Claim 3
Dependent Claim
21 words
A process of claim 3 wherein the salt of polyanethol sulfonic acid is introduced into the medium impregnated on a disc.
Claim 4
Dependent Claim
24 words
The process of claim 4 wherein the disc contains from about 0.1 mg. to about 1.0 mg. of the salt of polyanethol sulfonic acid.
Claim 5
Dependent Claim
88 words
A process for selectively inhibiting the growth of a mycoplasma selected from the group consisting of M. hominis, type 1; M. orale, type 2; M. fermentans; M. pulmonis; and mixtures thereof which comprises contacting a broth or agar medium containing the mycoplasma with a salt of sulfated polymannuronic acid, there being used in said process, based on the weight of the medium from about 0.5 percent to about 1.0 percent of the sulfated polymannuronic acid salt, incubating at about 37* C. and observing the growth of the culture.
Claim 6
Dependent Claim
21 words
The process of claim 6 wherein the salt of sulfated polymannuronic acid is introduced into the medium impregnated on a disc.
Claim 7
Dependent Claim
24 words
The process of claim 7 wherein the disc contains from about 0.1 mg. to about 0.2 mg. of the salt of sulfated polymannuronic acid.
Claim 8
Dependent Claim
86 words
A process for selectively inhibiting the growth of a mycoplasma selected from the group consisting of M. fermentans; M. orale, type 2; and M. pulmonis which comprises contacting a broth or agar medium containing the mycoplasma with a salt of sulfated polyglucuronic acid methyl ester, there being used in said process, based on the weight of the medium, from about 0.5 percent to about 1.0 percent of the sulfated polyglucuronic acid methyl ester salt, incubating at about 37* C. and observing the growth of the culture.
Claim 9
Dependent Claim
79 words
A process for selectively inhibiting the growth of the mycoplasma species M. pulmonis and M. orale, type 2 which comprises contacting a broth or agar medium containing the mycoplasma with a salt of sulfated polymannuronic acid methyl glycoside, there being used in said process, based on the weight of the medium, from about 0.5 percent to about 1.0 percent of the sulfated polymannuronic acid methyl glycoside salt, incubating at about 37* C. and observing the growth of the culture.
References Cited (Backward Citations)
US2694058A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1975-06-06 | 1975-12-06 | 1976-06-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1979-06-06 | 1979-12-06 | 1980-06-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1983-06-06 | 1983-12-06 | 1984-06-06 | $7700.00 | Window Closed / Lapsed |